he federal government spent a whopping $4.5 billion on costly new drugs to cure hepatitis C among Medicare patients last year, a steep price that is likely to keep growing, federal records show. Spending on the super-selling drugs – which can cost $1,000 a day – increased more than 15 times compared to the previous year, according to a report Monday by ProPublica.